Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:CKPT NASDAQ:OPNT NASDAQ:RVNC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$9.51+7.9%$8.52$56.35▼$105.00$275.65M0.9512,385 shs171,880 shsCKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.54 million shsN/AOPNTOpiant Pharmaceuticals$20.58$7.34▼$29.25$108.83M0.8477,920 shs562,700 shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.73 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-2.11%-16.18%+26.04%-90.85%-86.68%CKPTCheckpoint Therapeutics0.00%0.00%0.00%+5.45%+59.55%OPNTOpiant Pharmaceuticals0.00%0.00%0.00%0.00%0.00%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%-7.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACKPTCheckpoint Therapeutics0.476 of 5 stars1.20.00.04.21.80.00.0OPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARVNCRevance Therapeutics2.6736 of 5 stars3.10.00.04.70.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideOPNTOpiant Pharmaceuticals 0.00N/AN/AN/ARVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06OPNTOpiant Pharmaceuticals$47.78M0.00N/A24.75$9.92 per share0.00RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)CKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)OPNTOpiant Pharmaceuticals$3.01M-$6.56N/AN/AN/A-147.90%-97.03%-59.66%N/ARVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)Latest OPNT, RVNC, CKPT, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/A8/11/2025Q2 2025CKPTCheckpoint Therapeutics-$0.02N/AN/AN/A$7.28 millionN/A5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AOPNTOpiant PharmaceuticalsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CKPTCheckpoint TherapeuticsN/A0.290.29OPNTOpiant Pharmaceuticals0.605.485.48RVNCRevance TherapeuticsN/A4.123.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACKPTCheckpoint Therapeutics22.00%OPNTOpiant Pharmaceuticals42.39%RVNCRevance Therapeutics97.70%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CKPTCheckpoint Therapeutics2.10%OPNTOpiant Pharmaceuticals25.15%RVNCRevance Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableOPNTOpiant Pharmaceuticals375.27 million3.87 millionNot OptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableOPNT, RVNC, CKPT, and AVTE HeadlinesRecent News About These CompaniesRevance Names New CEO to Drive Next Phase in Aesthetic InnovationMay 23, 2025 | globalcosmeticsnews.comGRevance Announces Leadership Succession Plan to Support Next Phase of Growth and InnovationMay 21, 2025 | finance.yahoo.comCrown Laboratories Now Operates Under the Name RevanceMarch 31, 2025 | finance.yahoo.comJohnson City-based Crown Labs now operating as ‘Revance’March 31, 2025 | wjhl.comWREVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyMarch 4, 2025 | accessnewswire.comALevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCMarch 4, 2025 | accessnewswire.comARVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 4, 2025 | accessnewswire.comAContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | globenewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | accessnewswire.comARevance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCMarch 4, 2025 | accessnewswire.comAFINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action LawsuitMarch 4, 2025 | accessnewswire.comAInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 4, 2025 | prnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 3, 2025 | accessnewswire.comAMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCMarch 3, 2025 | accessnewswire.comARVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 3, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 3, 2025 | accessnewswire.comADeadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMarch 3, 2025 | businesswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCMarch 3, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming DeadlineMarch 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPNT, RVNC, CKPT, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$9.51 +0.70 (+7.95%) As of 07/17/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Checkpoint Therapeutics NASDAQ:CKPTCheckpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Opiant Pharmaceuticals NASDAQ:OPNTOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
